You are here: Industry Insights > ovarian cancer

News List

AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial americanpharmaceuticalreview
February 26, 2019
AIVITA Biomedical announced its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial.....
Losartan could improve ovarian cancer treatment europeanpharmaceuticalreview
January 17, 2019
Researchers have found that losartan could be beneficial for those undergoing cancer treatment as it may enhance its effectiveness…
Merck, Pfizer Terminate Avelumab Trial of Previously Untreated Advanced Ovarian Cancer americanpharmaceuticalreview
December 27, 2018
Merck and Pfizer have announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab did not support the study's initial hypothesis.....
Clovis should put itself up for sale, activist Armistice says: report fiercepharma
December 26, 2018
Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target.
Lynparza Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer americanpharmaceuticalreview
December 20, 2018
AstraZeneca and Merck announced the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or......
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 19, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
GSK enters PARP space with TESARO acquisition pharmaphorum
December 05, 2018
GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).....
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 21, 2018
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD)
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 20, 2018
Four out of five patients with ovarian cancer are diagnosed at advanced stages. The disease often has no symptoms early on, when it is much more treatable.
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 20, 2018
Four out of five patients with ovarian cancer are diagnosed at advanced stages. The disease often has no symptoms early on, when it is much more treatable.

Previous page 1 2 3 4 5 6 7 8 Next page